Corgentech announces patent issuance for E2F transcription factor decoy technology.
"We are very pleased by the issuance of the latest, and one of the most fundamental, United States patents protecting our E2F Decoy technology," said John P. McLaughlin, Corgentech's president and chief executive officer. "United States Patent 6,774,118 further solidifies our intellectual property position as we move toward commercial development of our lead product candidate."
In October 2003, Corgentech, Inc. and Bristol-Myers Squibb Company entered into an agreement to jointly develop and commercialize Corgentech's edifoligide (E2F Decoy), a first-of-its-kind treatment currently in Phase III development for the prevention of vein graft failure following coronary artery bypass graft and peripheral artery (i.e., leg) bypass graft surgery.
Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, such as arthritis and dermatitis, and cancer.
|Printer friendly Cite/link Email Feedback|
|Comment:||Corgentech announces patent issuance for E2F transcription factor decoy technology.|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Aug 1, 2004|
|Previous Article:||Lexicon extends intellectual property portfolio with patent on gene trapping.|
|Next Article:||GMP obtains two patents involving bag proteins and nucleic acid molecules encoding them and porous biodegradable polymeric materials for cell...|